
Chad, Sarah, Brittany& Linda are all never-smokers with RET-positive #lungcancer. They are parents, siblings, friends & spouses. This is their story. #lcsm @StephenVLiu @NarjustFlorezMD @VivekSubbiah youtube.com/watch?v=UJwRfb53…
✓Research, news and advocacy for caregivers and patients impacted by RET-driven cancers. Research is hope!🧬🔬

Chad, Sarah, Brittany& Linda are all never-smokers with RET-positive #lungcancer. They are parents, siblings, friends & spouses. This is their story. #lcsm @StephenVLiu @NarjustFlorezMD @VivekSubbiah youtube.com/watch?v=UJwRfb53…

Proud to announce our collaboration with @23andme + 19 lung cancer advocacy groups to advance the Lung Cancer Genetics Study. US #lungcancer survivors: pls join & help us drive life-saving scientific discoveries. #lcsm 23andme.com/lung-cancer/?utm…

‼️ #ASCO24 simultaneous publication by Williams et al: CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced #NSCLC: brnw.ch/21wKnSd

#ASCO24 Rapid Oral Presentation: Safety and efficacy of a selective RET inhibitor in pediatric and adolescent patients with RET-altered solid tumors. Results from the phase 1/2 LIBRETTO-121 study: e.lilly/4dVE5nU #CancerResearch #PrecisionMedicine

At #ASCO24, see our poster presentation examining a selective RET inhibitor in patients with non-MTC RET-mutated tumors. Results from the LIBRETTO-001 study: e.lilly/3x3gbpI #CancerResearch #PrecisionMedicine

At #ASCO24, we’re sharing intracranial outcomes data from LIBRETTO-431, a phase 3 study investigating front-line use of a selective RET inhibitor in patients with RET fusion+ advanced #NSCLC. Read the results here: e.lilly/4aB9ARm #CancerResearch #LungCancer #LCSM

Very important questions regarding management of other oncogene addicted nsclc in light of this data!

Excellent discussion from @LeciaSequist We can’t do the same for all oncogene driven tumours. Worth considering if there is CNS penetration and low tox. Access will be issue. #LCSM #ASCO24

Our latest blog features @TejasPatilMD as he highlights the importance of teamwork in #lungcancerresearch and why his work to study #MET & #EGFR signaling pathways may help us overcome drug resistance in multiple types of lung cancer. lungevity.org/blogs/kicking-… #RET #lcsm

Every year since 2018 we have gathered 5 or more year survivors of lung cancer together at CU to show others that hope has a face. This is the May 11th 2024 gathering. Rock on!


Targeting EGFR and MET pathways to overcome resistance to targeted therapies. Thanks to the Hamoui Foundation, Lungevity, Dr. Patil and partners for this exciting research-- potentially relevant for multiple drivers! lungevity.org/blogs/kicking-…

Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review frontiersin.org/journals/onc…

Thank you Dr. Watanabe, Lungevity and the patient community who helped fund this important research. #patientadvocacy #lcsm @LUNGevity

In our latest blog, Dr. Hideo Watanabe (@IcahnMountSinai) shares updates on what is happening in his lab that could improve the long-term effectiveness of targeted therapy treatment for #lungcancer patients. Read here: bit.ly/3Qui7hI @RETpositive
